Пошуковий запит: <.>A=Березін, О. Є.$<.> |
Загальна кількість знайдених документів : 120
Показані документи с 1 за 20 |
|
1.
| Berezin A. Predictive value of both irisin and apelin for heart failure with preserved ejection fraction in type 2 diabetes mellitus patients/A. Berezin, I. M. Fushtei, A. А. Berezin // European Journal of Preventive Cardiology, 2022. т.Vol. 29,N Suppl. 1.-С.zwac056.016.
|
2.
| Promising Novel Biomarkers in Cardiovascular Diseases/B. Sipos, P. Jirak, V. Paar, R. Rezar,M. Mirna, K. Kopp, U. C. Hoppe, A. E. Berezin, M. Lichtenauer // Applied Sciences. -Basel, 2021. т.Vol. 11,N N 8.- Ст.3654
|
3.
| Berezin A. Elevated levels of apelin predict favorable clinical course of heart failure in type 2 diabetes mellitus patients/A. Berezin, I. M. Fushtei, A. А. Berezin // European Journal of Preventive Cardiology, 2022. т.Vol. 29,N Suppl. 1.-С.zwac056.017
|
4.
| Heart Failure and Diabetes Mellitus: Biomarkers in Risk Stratification and Prognostication/M. Lichtenauer, P. Jirak, V. Paar, B. Sipos, K. Kopp, A.E. Berezin // Applied Sciences. -Basel, 2021. т.Vol. 11,N N 10.- Ст.4397
|
5.
| Berezin A. E. Metabolomics in Heart Failure Patients: Hype and Hope/A. E. Berezin // Biomarkers Journal, 2016. т.Vol. 2,N N 3.-С.e21-e23.
|
6.
| Berezin A. E. The Heart Failure Risk Predictive Scores Based on the Genetic Features: Hope and Hype/A. E. Berezin // Biological Markers and Guided Therapy:HIKARI Ltd, 2016. т.Vol. 3,N N 2.-С.221-226
|
7.
| Berezin A. E. Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes/A. E. Berezin, A. А. Berezin, M. Lichtenauer // Disease Markers, 2021,N N 3.-С.P. 6644631
|
8.
| Berezin A. E. Prognostication in different heart failure phenotypes: the role of circulating biomarkers/A. E. Berezin // Journal of Circulating Biomarkers:SAGE Publications, 2016. т.Vol. 5..-С.1-8
|
9.
| Petyunina O. V. Elevated levels of circulating soluble ST2 at discharge predict late adverse ventricular remodeling in patients with ST-segment elevation myocardial infarction/O. V. Petyunina, M. P. Kopytsya, A. E. Berezin // Biomedical Research And Therapy, 2018:Vol. 5,N N 12.-С.2863-2875
|
10.
| Berezin A. А. Low ratio of serum levels of apelin and NT-pro-BRAIN natriuretic peptide predicted the development of heart failure with preserved ejection fraction among type 2 diabetes mellitus patients/A. А. Berezin, I. M. Fushtei, A. E. Berezin // Atherosclerosis, 2021. т.Vol. 331.-С.P. Е277
|
11.
| Medvedkova S. А. Vascular endothelial growth factor-1 level and functional neurologic recovery after ischemic hemispheric stroke/S. А. Medvedkova, A. E. Berezin // Neurochemistry & neuropharmacology, 2015. т.Vol. 1,N N 1.-С.P. 1-4
|
12.
| Berezin A. E. Wellens syndrome: perennial unrecognisable pattern of acute coronary syndrome/A. E. Berezin // Acta Cardiologica, 2023. т.Vol. 78,N N 6.-С.742-744
|
13.
| Myocardial Mechanical Dispersion Predicts Adverse Cardiac Remodeling in Patients with ST Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention/O. Petyunina, M. Kopytsya, A. Kobets. A. Berezin // Turk Kardiyoloji Dernegi Arsivi, 2023. т.Vol. 51,N N 2.-С.119-128
|
14.
| Predictors of Kidney Function Outcomes and Their Relation to SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes Mellitus Who Had Chronic Heart Failure/T. A. Berezina, I. M. Fushtey, A. A. Berezin, S. V. Pavlov, A. E. Berezin // Advances in Therapy, 2024. т.Vol. 41,N N 1.-С.292-314
|
15.
| Association of growth-differentiation factor-15 with the number of circulating proangiogenic endothelial progenitor cells in patients with type 2 diabetes mellitus/A. E. Berezin, A. A. Kremzer, D. l. Petrovich, I. Mozos, A. A. Berezin // Biomedical Research And Therapy, 2018:Vol. 5,N N 7.-С.2480-2492
|
16.
| Berezin A. E. Emerging Role of the Fibroblast Growth Factor 23/Klotho Axis in Cardiovascular and Metabolic Conditions: A Narrative Review/А. Е. Berezin, S. V. Pavlov, O. P. Pakholchuk // Journal of Biochemical Technology, 2020. т.Vol. 11,N N 2.-С.P. 1-9
|
17.
| The utility of biomarker risk prediction score in patients with chronic heart failure/A. E. Berezin, A. A. Kremzer, Y. V. Martovitskaya, T. A. Samura, T. A. Berezina // Clinical Hypertension:BioMed Central, 2016,N N 3.-С.pp.1-3
|
18.
| Berezin A. E. Editorial: Epigenetics in Heart Failure Developing: The Orchestra of Etiology and Comorbidities/A. E. Berezin, I. Mozos, D. Petrovič // Frontiers in Cardiovascular Medicine, 2022. т.Vol. 9.-С.Article 869613
|
19.
| Berezin A. E. Can Osteoprotegerin be a Target of Therapy in Type 2 Diabetes Mellitus?/A. E. Berezin // Metabolomics: Open Access, 2016. т.Vol. 6,N N 2.-С.[рр. 5]
|
20.
| Interrelationship between insulin resistance and impaired immune phenotype of circulating endothelial-derived microparticles in none-diabetic patients with chronic heart failure/A. E. Berezin, A. A. Kremzer, T. A. Samura, Y. V. Martovitskaya, T. A. Berezina // Journal of Integrative Cardiology, 2015:Vol. 1,N N 2.-С.P. 46-51
|
|
|
|
На головну сторінку сайту
E-бібліотека навчальних матеріалів
Електронний каталог бібліотеки ЗДМФУ
Стандартний